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Abstract
Background: Autoantibodies against glutamate decarboxylase-65 (GAD65Abs) are thought to be a major
immunological tool involved in pathogenic autoimmunity development in various diseases. GAD65Abs are a
sensitive and specific marker for type 1 diabetes (T1D). These autoantibodies can also be found in 6-10% of
patients classified with type 2 diabetes (T2D), as well as in 1-2% of the healthy population. The latter individuals are
at low risk of developing T1D because the prevalence rate of GAD65Abs is only about 0.3%. It has, therefore, been
suggested that the antibody binding to GAD65 in these three different GAD65Ab-positive phenotypes differ with
respect to epitope specificity. The specificity of reactive oxygen species modified GAD65 (ROS-GAD65) is already well
established in the T1D. However, its association in secondary complications of T1D has not yet been ascertained.
Hence this study focuses on identification of autoantibodies against ROS-GAD65 (ROS-GAD65Abs) and quantitative
assays in T1D associated complications.
Results: From the cohort of samples, serum autoantibodies from T1D retinopathic and nephropathic patients
showed high recognition of ROS-GAD65 as compared to native GAD65 (N-GAD65). Uncomplicated T1D subjects also
exhibited reactivity towards ROS-GAD65. However, this was found to be less as compared to the binding recorded
from complicated subjects. These results were further proven by competitive ELISA estimations. The apparent
association constants (AAC) indicate greater affinity of IgG from retinopathic T1D patients (1.90 × 10
-6 M) followed by
nephropathic (1.81 × 10
-6 M) and uncomplicated (3.11 × 10
-7 M) T1D patients for ROS-GAD65 compared to N-GAD65.
Conclusion: Increased oxidative stress and blood glucose levels with extended duration of disease in complicated
T1D could be responsible for the gradual formation and/or exposing cryptic epitopes on GAD65 that induce
increased production of ROS-GAD65Abs. Hence regulation of ROS-GAD65Abs could offer novel tools for analysing
and possibly treating T1D complications.
Background
In autoimmune diabetes the autoantibodies have always
been important for clinical interest due to their potential
role in screening, diagnosis, monitoring treatment of
effectiveness and prognosis. The GAD65Abs are often
considered to be an epiphenomenon resulting from the
autoimmune destruction of the pancreatic beta cells in
T1D. Previous studies suggest that they are involved in
antigen processing and presentation and thus modulate
the immune response [1]. Because of the high diagnostic
sensitivity for autoimmune diabetes, the presence of
GAD65Ab is currently used to identify subjects at high
risk for the disease [2]. GAD65Abs are detected in about
60% of new-onset cases of type 1 diabetes [3], and high
levels of these autoantibodies were also reported in dia-
betic patients with secondary complications (such as
retinopathy and nephropathy), thus leading cause of
blindness and renal failure [4,5]. The exact etiology
behind these complications is not completely clear.
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to be more immunogenic in T1D than its native form
[6]. GAD65Abs in T1D are predominantly directed at
conformational epitopes located in the middle region of
the molecule, whereas they also recognize linear epi-
topes and epitopes located in the middle, COOH- and
NH2-terminuses [7,8]. Shifts in GAD65 epitopes were
detected in a subgroup of newly diagnosed children
within the first 12 months after disease onset [9]. More-
over, epitope spreading has gained credence as a major
driver underlying autoimmunity [10].
G r o w i n ge v i d e n c es u g g e s t st h a tR O Sp l a y sa ni m p o r -
tant role in the initiation and progression of diabetes
and its associated complications [11]. These increased
levels of free radicals pose a direct toxic effect on
GAD65 and increase its immunogenicity [6]. Specificity
of autoantibodies for epitopes on GAD65 and their levels
may be a better indicator of impending or actual
destruction of islet b-cells and increasing complications
associated with diabetes.
In the view of the above mentioned studies we hypothe-
sized some possible link between diabetic associated com-
plications and presence of ROS-GAD65Abs. To prove this,
binding characteristics of serum autoantibodies from
uncomplicated and complicated (nephropathic and retino-
pathic) T1D patients were assessed with N-GAD65 and
ROS-GAD65 by direct binding and competitive ELISA.
The avidity of modified GAD65 was also evaluated by pre-
cipitate titration curve in different diabetic groups.
Results
ROS modification of GAD65
ROS directed modification of GAD65 studied previously
by our group showed marked structural changes [6].
Khan et al., demonstrated that hyperchromicity and
tryptophan specific fluorescence for modified GAD65
was found to be significantly higher than native GAD65
and the spectral analysis also showed blue shift of 10
nm in modified GAD65 over native GAD65.F a r - U V - C D
spectropolarimetry of ROS-GAD65 exhibited significant
changes in secondary structural elements compared to
its unmodified form decrease in a-helix and an increase
of in b-sheet, random coil and turns was observed [6].
Detection of autoantibodies against N-GAD65 and ROS-
GAD65
In a pilot study serum samples from uncomplicated and
complicated T1D patients were screened for autoantibo-
dies against N-GAD65 (GAD65Abs) and ROS-GAD65
(ROS-GAD65Abs) using unmodified and ROS-modified
GAD65 as antigens. From Figure 1, we observed that
sera from normal human (NH) subjects showed very
low level of reactivity towards N-GAD65 [optical density
(OD); 0.07 ± 0.02] or ROS-GAD65 (OD; 0.08 ± 0.02).
Conversely, serum autoantibodies of uncomplicated
T1D patients showed significant binding with ROS-
GAD65 (OD; 0.58 ± 0.04, p<. 0 0 0 1 ) as compared to N-
GAD65 (OD; 0.35 ± 0.03). Moreover, sera from diabetic
nephropathic (OD; 0.83 ± 0.03, p < .0001)a n dd i a b e t i c
retinopathic (OD; 0.80 ± 0.05, p < .0001) patients exhib-
ited statistically higher significant differences in the
binding pattern of serum autoantibodies with ROS-
GAD65 as compared to N-GAD65 (nephropathic; 0.38 ±
0.05 and retinopathic; 0.40 ± 0.04).
OD was considered as a direct measure of the concen-
trations of autoantibodies in the serum samples. In all
the study groups there were higher levels of reactivity of
modified antigen as compared to its native form. NH
samples showed 14% increased and uncomplicated
serum samples exhibited 65.7% increased reactivity
towards ROS-GAD65 as compared to N-GAD65.
Whereas, nephropathic and retinopathic T1D compli-
cated subjects showed an increase of 118.4% and 100%
respectively, in the reactivity with modified antigen
when compared with unmodified antigen.
The binding specificities of serum autoantibodies from
uncomplicated and complicated (Nephropathic and reti-
nopathic) T1D patients were evaluated by competitive
ELISA using N-GAD65 and ROS-GAD65 as inhibitors. Sig-
nificantly higher recognition of modified antigen was
observed by the serum autoantibodies from nephropathic
[70.3 ± 8.2 mean maximum percent inhibition (MMPI)]
and retinopathic patients (74.5 ± 6.5 MMPI] as compared
to uncomplicated T1D serum samples (50.6 ± 7.2 MMPI).
N-GAD65 exhibited no marked difference in recognition
of serum IgG from both complicated [nephropathy (39.2 ±
5.4 MMPI) and retinopathy (41.1 ± 5.3 MMPI)]
Figure 1 Detection of serum autoantibodies against both
native and modified GAD65 in all subjects. Direct binding ELISA
of 1:100 diluted uncomplicated and complicated (nephropathy and
retinopathy) T1D serum samples. Control samples were served as
controls. Serum autoantibodies reactivity of all four groups was
checked towards N-GAD65 (□) and ROS-GAD65 (■). Microtitre plates
were individually coated with N-GAD65 and ROS-GAD65 (20 μg/ml).
Each histogram represents the mean ± SD values.
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Table 1. Normal humans showed very less or negligible
percent inhibition with either of the antigens [N-GAD65
(7.3 ± 3.6 MMPI) and M-GAD65 (7.2 ± 3.2 MMPI)].
Estimation of protein bound carbonyl compounds in
serum samples
In vivo carbonyl content was considered a biomarker of
oxidative stress. Oxidative stress levels were estimated
for every patient of each group of T1D (Table 2). Data
showed significant increase in serum protein bound car-
bonyl contents (p < 0.001) in complicated subjects as
compared to uncomplicated T1D patients. Complicated
subjects, T1D who had retinopathy (3.9 ± 0.31 nmoles/
mg protein) exhibited higher amounts of protein bound
carbonyl content as compared to nephropathic (3.4 ±
0.28 nmoles/mg protein) T1D patients.
Quantification of apparent association constant
The amount of antigen bound to antibody was also
evaluated by quantitative precipitin titration curve. IgG
o fu n c o m p l i c a t e d( s e r u mn o .1 1 )a n dc o m p l i c a t e d
[nephropathic (serum no. 3) and retinopathic (serum
no. 6)] subjects was purified by affinity chromatography
on Protein A-Agarose column. The purified IgGs were
found to elute in a single symmetrical peak. Varying
amounts of modified GAD65 (0-40 μg) were mixed with
100 μgo fp a t i e n t ’s IgG and incubated for 2 h at 37°C
and overnight at 4°C. Microsurface adsorption-spectral
correction (MSASC) technique showed the interaction
of IgG with modified protein. Langmuir equation was
used to estimate AAC of complicated and uncompli-
cated T1D samples for ROS-GAD65 (Figure 2) and was
computed to be 1.81 × 10
-6 Ma n d1 . 9 0×1 0
-6 Mf o r
T1D nephropathic and retinopathic patients respec-
tively. Uncomplicated T1D showed 3.11 × 10
-7 M AAC.
Am a x i m u mo f2 3μga n d2 0μgo fR O S - G A D 65 was
bound to 84 μga n d8 7μg of IgG from T1D nephro-
pathic and retinopathic subjects respectively. However
uncomplicated T1D patients exhibited 28 μgo fI g G
bound with 76 μgo fR O S - G A D 65. No appreciable
differences were observed in the AACs calculated
for N-GAD65 in same above mentioned serum samples
of complicated (nephropathic; 2.87 × 10
-7 Ma n d
Table 1 Inhibition of serum IgG from uncomplicated T1D, complicated T1D and control subjects towards native and
modified GAD65
Maximum percent inhibition at 20 μg/ml
Serum Uncomplicated T1D Nephropathic T1D Retinopathic T1D Controls
N-GAD65 M-GAD65 N-GAD65 M-GAD65 N-GAD65 M-GAD65 N-GAD65 M-GAD65
1 3 65 44 07 83 98 5 - -
2 3 84 04 26 63 77 9 - 7
3 4 76 15 47 94 45 771 1
4 3 75 54 17 04 16 8 - -
5 4 34 94 86 63 26 5 - -
6 3 55 43 57 43 77 9 -1 0
7 4 06 04 45 64 37 61 07
8 2 66 83 97 35 15 7 - -
9 2 23 73 05 93 67 079
10 38 56 37 62 50 77 8 5
11 45 63 42 57 40 70 - 7
12 34 50 29 59 48 69 - -
13 46 55 37 76 50 79 5 9
14 41 52 36 69 36 75 - -
15 33 39 39 78 33 81 - -
16 21 48 28 79 30 83 6 7
17 19 41 26 69 28 78 8 6
18 26 37 27 75 37 79 6 7
19 31 45 35 81 35 82 9 8
20 28 47 39 80 40 80 - -
Mean ± SD 35.2 ± 5.9 50.6 ± 7.2 39.2 ± 5.4 70.3 ± 8.2* 41.1 ± 5.3 74.5 ± 6.5* 7.3 ± 3.6 7.2 ± 3.7
N-GAD65 and M-GAD65 represents Native GAD65 and modified GAD65.
NH represents normal humans as control.
The ELISA plates were coated with N-GAD65 and M-GAD65 (20 μg/ml).
ROS-GAD65 and N-GAD65 were used as inhibitor.
* p < 0.001 vs ROS-GAD65Abs in uncomplicated T1D.
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-7 M) and uncomplicated T1D
patients (2.63 × 10
-7 M) as shown in Figure 3.
Discussion
The levels of ROS increase many folds during T1D via
formation of sorbitol by polyol pathways, regeneration of
cofactors NADPH and NAD
+ by NAD(P)H oxidase and
glycation reactions [12,13]. Long term association of pro-
teins with high concentrations of hydrogen peroxide and
free radical intermediates results in protein modification
both at the amino acid and protein levels [14]. This state-
ment is supported by our previous findings based on the
structural characterization of native and ROS-GAD65
(increased UV-absorbance and tryptophan fluorescence
and changes in secondary structural elements) [6].
Significant recognition of ROS-GAD65 by serum auto-
antibodies of complicated T1D patients was estimated
when compared with autoantibodies from uncompli-
cated T1D subjects. N-GAD65 did not show any marked
differences in recognitions of circulatory autoantibodies
from complicated and uncomplicated T1D subjects. The
affinity of GAD65Abs was found to be higher in subjects
who had developed T1D with neuropathy [15] or auto-
immune polyendocrine disorders [16]. In control normal
humans, negligible binding was observed with either of
the antigens.
Table 2 Clinical and laboratory data from complicated and uncomplicated T1D patients; normal human subjects serve
as controls
Subjects Number
of sera
Age
(years ± SD)
Gender
(M:F)
Smoking
duration n
(years ± SD)
Duration of
disease
(years ± SD)
Fasting blood
glucose (mg/dl)
HbA1C
(%)
Hyperten-
sion 140/90
(%)
Carbonyl Content
(nmol/mg
protein)
Uncomplic-
ated T1D
60 30 ± 09 37:23 8(5 ± 3.4) 09 ± 5.6 238 ± 27
# 7.9 ±
0.7
36(60) 3.0 ± 0.22
#
Complicated
T1D
Nephropathy
20 37 ± 11 12:8 14(6 ± 3.8) 14 ± 4.9 311 ± 21* 8.8 ±
0.6*
17(85) 3.4 ± 0.28*
Complicated
T1D
Retinopathy
20 42 ± 14 11:9 17(8 ± 3.6) 17 ± 4.3 335 ± 17* 9.3 ±
0.7*
16(80) 3.9 ± 0.31*
Control 50 32 ± 8 28:22 –– 96 ± 11.2 5.8 ±
0.4
4(8) 2.1 ± 0.17
Data are means ± SD or n represents number of smokers from given total respective subjects. For blood glucose estimations, blood was collected in oxalated
fluoride containers and the assays were performed immediately. Hypertension is defined as sitting systolic blood pressure ≥ 140 mmHg and/or diastolic blood
pressure ≥ 90 mmHg or the use of antihypertensive medication. Signs * and
# represents p values < 0.001 and < 0.05 respectively.
Figure 2 Determination of apparent association constants for
ROS-GAD65 by Langmuir plot. Langmuir plot of reciprocal of
bound antigen concentration to antibody (1/r) versus reciprocal of
free antigen concentration (1/[Ag]). Antigen and antibody binding
between ROS-GAD65 and IgG isolated from nephropathic (-■-)
serum no.3, retinopathic (-●-) serum no. 6 of complicated T1D and
uncomplicated (-▲-) (serum no. 11) T1D subjects. Each value
represents mean ± SD of four independent assays.
Figure 3 Determination of apparent association constant for N-
GAD65 by Langmuir plot. Langmuir plot of reciprocal of bound
antigen concentration to antibody (1/r) versus reciprocal of free
antigen concentration (1/[Ag]). Antigen and antibody binding
between N-GAD65 and IgG from nephropathic (-■-) serum no.3,
retinopathic (-●-) serum no. 6 complicated T1D and uncomplicated
(-▲-) (serum no. 11) T1D subjects. Each value represents mean ± SD
of four independent assays.
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complicated (nephropathic and retinopathic) and
uncomplicated T1D patients were selected and binding
affinities of circulating autoantibodies with N-GAD65
and ROS-GAD65 were ascertained by competitive
ELISA. Twenty serum samples from normal humans
were taken under the same experimental condition as
controls. A characteristic difference was observed in the
pattern of inhibition ELISA assays obtained from com-
plicated and uncomplicated T1D subjects in respect to
ROS-GAD65 antigen. This indicates that the ROS-modi-
fied GAD65 is an effective inhibitor showing substantial
higher titres of circulating autoantibodies in complicated
T1D subjects as compared to uncomplicated T1D.
Moreover; amongst the complicated patients, retino-
pathic showed highest recognition for ROS GAD65 as
compared to nephropathic and uncomplicated patients.
Further the study also elucidates that with increased
duration of disease and poor glycemic control leads to
increased oxidative stress and hence the complications.
The oxidative stress was further ascertained by the levels
of protein bound carbonyl content in patients which is a
biomarker of protein oxidation [17]. Type 1 diabetes
retinopathic patients had highest carbonyl content fol-
lowed by nephropathic and uncomplicated respectively.
Possible this heightened state of oxidative stress leads to
extensive in vivo GAD65 antigen modifications. Thus
GAD65 of complicated T1D patients presents more
number of epitopes that resemble in vitro ROS modified
GAD65 and conceivably generates significant number of
autoantibodies. GAD65Ab titers are higher and more
prevalent in patients with other associated autoimmune
diseases such as thyroiditis [18]. The strong dependence
of conformation of protein for autoantibody recognition,
blocking experiments [19] and recombinant Fab using
monoclonal antibodies [16,20] has been useful for deter-
mining conformational GAD65Ab epitopes.
During immune-pathophysiology significant amounts
of circulating immune complexes are formed and depos-
ited in kidneys leading to diabetic nephropathy, retino-
pathy and other tissues causing severe injury [21]. As
we discussed in this study continuous long durations of
increased levels of ROS cause increase in antigenic
determinants on GAD65. So, the avidity of GAD65
became more complex and gain increased strength
of binding because of interdependency of epitopes.
Figure 2 and 3 clearly indicate better recognition of
ROS-GAD65 than N-GAD65 by IgG isolated from retino-
pathic T1D subjects followed by nephropathic and
uncomplicated T1D patient. The enhanced recognition
of ROS-GAD65 by retinopathic T1D patient IgG showed
the possible participation of oxidative stress and long
duration of disease as given in Table 2 that might have
role in in vivo modification of GAD65 inducing the
molecule to express its cryptic epitopes.
Conclusion
In conclusion, significantly high levels of circulating
ROS-GAD65Abs were detected in complicated (retino-
pathic and nephropathic) as compared to uncompli-
cated T1D patients. This risk of the disease may be
exemplified due to acceleration in the formation of
free radicals with gradual increase in duration of dis-
ease. This leads to conformational alterations in N-
GAD65 protein which could increase or expose cryptic
epitopes. Dynamic changes in the GAD65Abs binding
pattern suggest subsequent epitopes spreading with
disease progression. This could be one of the etiologies
of increased GAD65Ab immunogenicity that implicated
in T1D complications. Measurement of these autoanti-
bodies could be shown to be useful in assisting the
prediction for the development of T1D progression/or
complications. Reduction in the levels of ROS may
lead to decrease in in vivo GAD65 molecules modifica-
tion thus, leads to delay in the progression of compli-
cations. Hence antioxidants may play important role in
the treatment.
Methods
Human serum samples
In the present study 100 T1D (60 uncomplicated and 40
complicated) and 50 control normal human (NH) sub-
jects were investigated. All the patients were on the
insulin treatment with suitable doses depending on the
clinical examinations. All the serum samples of patients
were collected from the laboratory of Endocrinology,
Department of Medicine (J. N. Medical College and
Hospital, A. M. University, Aligarh, India) and their clin-
ical features are shown in Table 2. Approximately 20 ml
of fasting venous blood was collected from each subject.
For estimation of glucose, blood was taken in oxalated
fluoride containers and the assays were performed
immediately. Isolated serum samples from all subjects
were heated at 56°C for 30 min to deactivate comple-
ment protein and stored at -20°C with sodium azide.
The categories for diabetic complications were mutually
exclusive. Normal humans served as controls, age and
sex matched with no family history of diabetes. All
groups underwent periodic examinations. All subjects
gave informed consent to the analysis and the study had
Ethics Committee approval. Patient classification is sum-
marized as follows.
Uncomplicated patients
These patients (n = 60) have had T1D and remained
free from any complications (retinopathy and nephropa-
thy). These patients are negative proteinuria.
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These patients (n = 20) had T1D and all were protei-
nuria positive (urinary protein excretion rates ≥300 mg/
24 h) in the absence of hematuria or infection in mid-
stream urine samples.
Retinopathic patients
These patients (n = 20) had retinopathy defined as hav-
ing more than five dots or blots per eye; hard or soft
exudates and vitreous hemorrhage.
Preparation of Antigen
Human-GAD65 (G-2126, Type II: from E. coli, Sigma,
St. Louis, MO, USA) was modified with hydroxyl radi-
cals. Briefly, solution (3.0 ml total volume) of N-GAD65
(100 mg/ml) in 50 mM sodium phosphate buffer, pH
7.4, was irradiated with 254 nm UV light for 30 min at
room temperature in the presence of 10 mM hydrogen
peroxide (Genei, Bangalore, India). After modification,
extensive dialysis has been was done with 50 mM
sodium phosphate buffer to remove excess hydrogen
peroxide and hydroxyl radicals. Protein concentration
determined by Bradford’s method [22].
Protein bound carbonyl groups
Protein bound carbonyl groups from sera of different dia-
betic groups and NH subjects were analyzed according to
Levine et al. [23] and the results were expressed as the
number of nanomoles of carbonyl per mg of sample pro-
tein using a ε379 = 22,000 M
-1.cm
-1. Protein concentration
of the samples was determined by Bradford’s method [22].
Elisa
Direct binding ELISA was performed on polystyrene
microtitre flat bottom plates (NUNC, Roskilde, Den-
mark), as described previously [6,24]. Briefly plates were
coated with 100 μl of respective antigen (20 μg/ml) for
2 h at room temperature and overnight at 4°C. The
plates were washed with TBS-T (20 mM Tris, 2.68 mM
KCl, 150 mM NaCl, pH 7.4, containing 0.05% Tween-
20) and unoccupied sites were blocked with 150 μlo f
1.5% BSA in TBS (10 mM Tris, 150 mM NaCl, pH 7.4)
for 4-6 h at room temperature. The test serum (diluted
1:100) in TBST (100 μl per well) was adsorbed for 2 h
at room temperature and overnight at 4°C. Bound anti-
bodies were assayed with anti-human IgG alkaline phos-
phatase conjugate (Sigma, St. Louis, MO, USA) using
para-nitrophenyl phosphate (Sigma, St. Louis, MO,
USA) as substrate. The absorbance of each well was
monitored at 410 nm on an automatic microplate reader
(Labsystem Multiskan EX, Helsinki, Finland).
Competitive ELISA
The antigenic specificity of modified GAD65 was deter-
mined by competitive ELISA [6,24]. Varying concentrations
of inhibitors (0-20 μg/ml) were allowed to interact with a
constant amount of serum antibody (1:20 diluted serum)
for 2 h at room temperature and overnight at 4°C. The
immune complex thus formed was incubated in the wells
and the bound antibody levels were detected as in direct
binding ELISA.
The percent inhibition was calculated using the for-
mula:
Percent inhibition = [1 − (Ainhibited/Auninhibited) × 100]
Where A inhibited is the absorbance at 20 μg/ml of
inhibitor concentration and A uninhibited the absorbance
at zero inhibitor concentration.
IgG isolation
Immunoglobulin G was isolated from uncomplicated
and complicated T1D sera on Protein A-Sepharose
CL-4B column (Genei, Bangalore, India) [25]. The
homogeneity of isolated IgG was checked by 7.5% polya-
crylamide gel electrophoresis.
Quantitation of antigen-antibody immune complex
One hundred micrograms of IgG was incubated with
varying amounts of ROS-GAD65 a n t i g e ni na na s s a y
volume of 500 μl. The mixture was incubated for 2 h at
room temperature and overnight at 4°C. The immune
complexes were pelleted, washed twice with PBS and
dissolved in 250 μl of 1 N NaCl. Protein concentrations
were measured by colorimetric method [22]. The bind-
ing data were analyzed for antibody affinity [26].
Statistical evaluation
The values are given as arithmetic mean ± SD wherever
indicated. Multiple comparisons were analyzed by stu-
dent t test using SPSS16 software program and p < 0.05
was considered to be statistically significant.
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